What is Celltrio?
Celltrio, Inc. operates at the intersection of biotechnology and advanced robotics, providing high-value automation solutions designed to streamline complex laboratory processes. The company addresses a critical bottleneck in the life sciences sector: the time-intensive and costly nature of manual cell culture and harvesting. By deploying sophisticated automation, Celltrio enables research institutions and pharmaceutical firms to significantly reduce operational overhead while increasing the reproducibility and speed of experimental outcomes. This market position is increasingly vital as the industry shifts toward faster drug discovery cycles and the need for scalable, error-free biological processing environments.
How much funding has Celltrio raised?
Celltrio has raised a total of $30M across 2 funding rounds:
Other Financing Round
$15M
Private Equity
$15M
Other Financing Round (2025): $15M with participation from AEG Premier Partner
Private Equity (2025): $15M, investors not publicly disclosed
Key Investors in Celltrio
AEG Premier Partner
A strategic partner focused on supporting business growth through superior service, innovative technology, and a commitment to exceeding operational standards.
Undisclosed Investor
An undisclosed institutional investor participating in the recent financing round to support Celltrio's growth trajectory.
Undisclosed Investor
An undisclosed private equity participant providing capital to fuel the expansion of Celltrio's automation capabilities.
What's next for Celltrio?
With this recent capital, Celltrio is expected to scale its enterprise-level operations and expand its footprint in the global biobanking market. The strategic focus will likely center on enhancing its proprietary automation platforms to support broader applications in cell line development. As the demand for efficient drug development pipelines continues to rise, Celltrio is poised to leverage this financial backing to solidify its competitive advantage, potentially through increased R&D investment and the expansion of its service infrastructure to support large-scale clinical and research deployments.
See full Celltrio company page
